Alexander Gintsburg, a member of the Russian Academy of Sciences and the scientific director of the Gamaleya National Research Center for Epidemiology and Microbiology, announced that Russia plans to develop three new cancer vaccines.
He told the Russian news agency Novosti: "In the future, we plan to develop vaccines for bladder cancer, small cell lung cancer, and colorectal cancer."
Gintsburg had announced last April that the first patient had received the experimental Russian vaccine for treating skin cancer (melanoma), noting at the beginning of this month that the patient, aged 60, had shown remarkable improvement, with a good immune response to the vaccine.
Russian scientists are currently working on developing several anti-cancer vaccines, including a vaccine for skin cancer (melanoma), which is being developed in collaboration between the Gamaleya National Research Center for Epidemiology and Microbiology, the Herzen Research Institute of Oncology in Moscow, and the Blokhin National Medical Research Center for Oncology.
Research is also continuing to develop a vaccine to treat brain tumors, in addition to two vaccines to treat colorectal cancer: a peptide vaccine called "Oncopept" and a messenger RNA (mRNA) vaccine known as "Oncorna," both of which aim to stimulate the immune system to recognize and attack cancer cells.
Russian Prime Minister Mikhail Mishustin announced last April that Russian citizens would be able to receive these treatments under Russia’s mandatory health insurance program.
